http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
엔로플록사신 액제의 닭유래 병원세균에 대한 시험관내 항균효과 시험
윤효인,박병권,조준형,정상희,박경환,장범수,김종춘,황윤환,임종환,이내경,박승춘 충남대학교 수의과대학 동물의과학연구소 2000 動物醫科學硏究誌 Vol.8 No.-
In this study the antimicrobial spectrum and sensitivity of a liquid formulation of enrofloxacin against the major six pathogenic bacteria isolated from the diseased poultry in Korea were evaluated in comparison with ciprfloxacin (CFX), gentamicin (GM) and penicillin (PC). A liquid form of enrofloxacin, a test material and ciprofloxacin showed at least 83% antibacterial activity against all of six test pathogenic microorganisms at the fixed concentration of 10 ㎍/㎖. Gentamicin and penicillin revealed much lower antibacterial activity at the same condition. We evaluated the liquid form of enrofloxacin as having widespread antibacterial spectrum against poultry infections. The liquid form of enrofloxacin showed potent antibacterial activity, with the MIC range being 0.12∼2 ㎍/㎖ against Gram positives, 0.06∼2 ㎍/㎖ against Gram negatives and 0.5∼2 ㎍/㎖ against Mycoplasma spp. These values were equivalent to or somewhat higher than those of ciprofloxacin, but much lower than those of gentamicn and penicillin. This new liquid form of enrofloxacin would find its way in application of mixing with drinking water for the prevention and treatment of diverse infections in chickens.
엔로플록사신 액제의 닭 호흡기 및 소화기 감염증에 대한 예방 및 치료효과
윤효인,박병권,조준형,정상희,박경환,장범수,김종춘,황윤환,임종환,이내경,박승춘 충남대학교 수의과대학 동물의과학연구소 2000 動物醫科學硏究誌 Vol.8 No.-
We evaluated the efficacy of the liquid form of enrofloxacin against poultry respiratory and digestive infections, the major problems in the poultry industry, from diverse diagnosis viewpoints. Results obtained through this study were as follows: 1. The liquid form of enrofloxacin showed good acceptability to poultry owing to no abhorrence to the drug by chickens, which indicated its suitability for mixing in drinking water. 2. The application of the enrofloxacin formulation improved the productivity of the chicken farm to a great extent by lowering the death toll of chicken raised in the farm. 3. The use of the drug shortened the days to the market, and increased the body weight at the time of marketing. 4. Preventive and therapeutic effects of the liquid enrofloxacin were observed higher than ampicillin, a major antibiotic used in poultry farming. From above results, the liquid form of enrofloxacin would find its use for the prevention and treatment of digestive and respiratory infections, let alone the growth promotion and feed efficiency, especially in the chicken farming practice.
토끼에서 근육주사시 입자 크기에 따른 amoxicillin의 비교 약물동태학
박승춘,윤효인,오태광,장범수,배순이,조준형,정상희,이내경,김민규 충남대학교 수의과대학 동물의과학연구소 1998 動物醫科學硏究誌 Vol.6 No.-
To investigate the pharmacokinetic difference between the two amoxicillin (AMX) particles in rabbits after intramuscular injection (i.m.), both of AMX-S (particle size: 10 ㎍) and AMX-L (particle size: 100 ㎍) were injected into New Zealand White rabbits (1.2±0.3 ㎏) at a dose rate of 10 ㎎/㎏ of body weight. In this study, serum AMX concentrations were detected by microbiological assay with E. coli BE 1186 which shows high antibiotic sensitivity. After i.m. administration, AMX-S and AMX-L were best fitted as 1-compartment model with the absorption and elimination phase. The biological half-life (T_1/2, _k10) of AMX-S is 4.06±1.09 h and that of AMX-L 4.76±0.69 h. The serum maximal concentration time (T_max) of AMX-S and AMX-L were 0.88±0.17 h and 0.77±0.11 h, respectively. Maximal AMX concentration (C_max) (AMX-S: 5.71±0.62 ㎍/㎖, AMX-L: 5.04±0.25 ㎍/㎖) in serum showed a significant difference (p<0.05). In terms of bioequivalance, however, there was no difference between the two AMX's after i.m. injection in the basis of C_max and AUC.
Nam Jun Cho,Ho-Sung Lee,Si-Hyong Jang,Jae Sung Choi,Ju Ock Na,Ki Hyun Seo,Yong Hoon Kim,Hyo-Chul Kang,Dae-Yeon Kim1 순천향의학연구소 2013 Journal of Soonchunhyang Medical Science Vol.19 No.2
In patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations, the epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are used as first treatment option. Because adenosquamous carcinoma (ASC) is a rare histologic subtype, evidences about EGFR-TKIs as first treatment option for advanced ASC are lacking. We report a case of an advanced ASC patient with the EGFR mutation, who showed good responses during 4-month treatment with gefitinib. And we will review about a necessity of EGFR mutation test and efficacy of EGFR-TKIs in ASC patients from the recent studies.